Terms ending in 2034
Every in-force patent on Genmab A/S's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,590,206 | Inert Format In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,323,081 | Modulation of Complement-Dependent Cytotoxicity Through Modifications of the C-Terminus of Antibody Heavy Chains In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,485,796 | Inert Format In force · High confidence | Genmab A/S | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.